Type 2 Cardiorenal Syndrome | | 2021 |
Glifozines and cardiorenal outcomes | Minerva Cardioangiologica | 2020 |
Range of adiposity and cardiorenal syndrome | World Journal of Diabetes | 2020 |
Consensus document: management of heart failure in type 2 diabetes mellitus | Heart Failure Reviews | 2021 |
Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure | Russian Journal of Cardiology | 2021 |
Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure | Clinical Diabetes | 2021 |
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis | JAMA Cardiology | 2021 |
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention | American Journal of Cardiovascular Drugs | 2020 |
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment | Nature Reviews Cardiology | 2020 |
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials | Diabetes Therapy | 2020 |
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials | Diabetes Therapy | 2020 |
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure | European Journal of Internal Medicine | 2020 |
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin? | Current Vascular Pharmacology | 2019 |
Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future | BMC Medicine | 2019 |
Cardiovascular Protection with Anti-hyperglycemic Agents | American Journal of Cardiovascular Drugs | 2019 |
Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes | Journal of Diabetes | 2019 |
Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes | Diabetes, Obesity and Metabolism | 2019 |
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis | Cardiovascular Diabetology | 2019 |
Cardiovascular outcome trials of the newer anti-diabetic medications | Progress in Cardiovascular Diseases | 2019 |
SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects | Journal of the American Heart Association | 2019 |
Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More? | JACC Basic To Translational Science | 2019 |
Are Sodium-Glucose Cotransporter 2 Inhibitors Really Useful and Safe for Advanced Heart Failure? | Circulation Journal | 2018 |
The treatment of type 2 diabetes in heart failure | Practical Diabetes | 2018 |
SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials | Current Diabetes Reports | 2018 |
Effect of glucose-lowering therapies on heart failure | Nature Reviews Cardiology | 2018 |
The CANVAS trial programme raises more questions than answers | Practical Diabetes | 2017 |
Novel Diabetes Drugs and the Cardiovascular Specialist | Journal of the American College of Cardiology | 2017 |